Literature DB >> 21081502

Neuroprotection by minocycline caused by direct and specific scavenging of peroxynitrite.

Stefan Schildknecht1, Regina Pape, Nathalie Müller, Marta Robotta, Andreas Marquardt, Alexander Bürkle, Malte Drescher, Marcel Leist.   

Abstract

Minocycline prevents oxidative protein modifications and damage in disease models associated with inflammatory glial activation and oxidative stress. Although the drug has been assumed to act by preventing the up-regulation of proinflammatory enzymes, we probed here its direct chemical interaction with reactive oxygen species. The antibiotic did not react with superoxide or (•)NO radicals, but peroxynitrite (PON) was scavenged in the range of ∼1 μm minocycline and below. The interaction of pharmacologically relevant minocycline concentrations with PON was corroborated in several assay systems and significantly exceeded the efficacy of other antibiotics. Minocycline was degraded during the reaction with PON, and the resultant products lacked antioxidant properties. The antioxidant activity of minocycline extended to cellular systems, because it prevented neuronal mitochondrial DNA damage and glutathione depletion. Maintenance of neuronal viability under PON stress was shown to be solely dependent on direct chemical scavenging by minocycline. We chose α-synuclein (ASYN), known from Parkinsonian pathology as a biologically relevant target in chemical and cellular nitration reactions. Submicromolar concentrations of minocycline prevented tyrosine nitration of ASYN by PON. Mass spectrometric analysis revealed that minocycline impeded nitrations more effectively than methionine oxidations and dimerizations of ASYN, which are secondary reactions under PON stress. Thus, PON scavenging at low concentrations is a novel feature of minocycline and may help to explain its pharmacological activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21081502      PMCID: PMC3037611          DOI: 10.1074/jbc.M110.169565

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

Review 1.  Clinical pharmacokinetics of doxycycline and minocycline.

Authors:  S Saivin; G Houin
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

Review 2.  The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases.

Authors:  J B Schulz; R T Matthews; T Klockgether; J Dichgans; M F Beal
Journal:  Mol Cell Biochem       Date:  1997-09       Impact factor: 3.396

3.  The mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity: role of intracellular calcium.

Authors:  G E Kass; J M Wright; P Nicotera; S Orrenius
Journal:  Arch Biochem Biophys       Date:  1988-02-01       Impact factor: 4.013

4.  Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice.

Authors:  Shan Zhu; Irina G Stavrovskaya; Martin Drozda; Betty Y S Kim; Victor Ona; Mingwei Li; Satinder Sarang; Allen S Liu; Dean M Hartley; Du Chu Wu; Steven Gullans; Robert J Ferrante; Serge Przedborski; Bruce S Kristal; Robert M Friedlander
Journal:  Nature       Date:  2002-05-02       Impact factor: 49.962

5.  Neuronal DNA damage precedes tangle formation and is associated with up-regulation of nitrotyrosine in Alzheimer's disease brain.

Authors:  J H Su; G Deng; C W Cotman
Journal:  Brain Res       Date:  1997-11-07       Impact factor: 3.252

Review 6.  The promise of minocycline in neurology.

Authors:  V Wee Yong; Jennifer Wells; Fabrizio Giuliani; Steven Casha; Christopher Power; Luanne M Metz
Journal:  Lancet Neurol       Date:  2004-12       Impact factor: 44.182

7.  Acetaminophen inhibits prostanoid synthesis by scavenging the PGHS-activator peroxynitrite.

Authors:  Stefan Schildknecht; Andreas Daiber; Sandro Ghisla; Richard A Cohen; Markus M Bachschmid
Journal:  FASEB J       Date:  2007-08-27       Impact factor: 5.191

8.  Tyrosine nitration of IkappaBalpha: a novel mechanism for NF-kappaB activation.

Authors:  Vasily A Yakovlev; Igor J Barani; Christopher S Rabender; Stephen M Black; J Kevin Leach; Paul R Graves; Glen E Kellogg; Ross B Mikkelsen
Journal:  Biochemistry       Date:  2007-10-02       Impact factor: 3.162

9.  Doxycycline is neuroprotective against nigral dopaminergic degeneration by a dual mechanism involving MMP-3.

Authors:  Yuri Cho; Hyo Jin Son; Eun-Mee Kim; Ji Hyun Choi; Sung Tae Kim; In Jung Ji; Dong Hee Choi; Tong H Joh; Yoon Seong Kim; Onyou Hwang
Journal:  Neurotox Res       Date:  2009-07-07       Impact factor: 3.911

10.  A modified and automated version of the 'Fluorimetric Detection of Alkaline DNA Unwinding' method to quantify formation and repair of DNA strand breaks.

Authors:  María Moreno-Villanueva; Ragen Pfeiffer; Thilo Sindlinger; Alan Leake; Marcus Müller; Thomas B L Kirkwood; Alexander Bürkle
Journal:  BMC Biotechnol       Date:  2009-04-23       Impact factor: 2.563

View more
  31 in total

Review 1.  Central nervous system myeloid cells as drug targets: current status and translational challenges.

Authors:  Knut Biber; Thomas Möller; Erik Boddeke; Marco Prinz
Journal:  Nat Rev Drug Discov       Date:  2015-12-04       Impact factor: 84.694

2.  Minocycline increases the activity of superoxide dismutase and reduces the concentration of nitric oxide, hydrogen peroxide and mitochondrial malondialdehyde in manganese treated Drosophila melanogaster.

Authors:  Marylú Mora; Ernesto Bonilla; Shirley Medina-Leendertz; Yanauri Bravo; José Luis Arcaya
Journal:  Neurochem Res       Date:  2014-04-23       Impact factor: 3.996

3.  Gastroprotective effect of minocycline in experimentally induced gastric ulcers in rats.

Authors:  Abdulrahman Al Asmari; Saud Al Omani; Malfi Al Otaibi; Abdul-Aziz Al Abdulaaly; Ibrahim Elfaki; Khalid Al Yahya; Mohammed Arshaduddin
Journal:  Int J Clin Exp Med       Date:  2014-03-15

4.  Early minocycline treatment prevents a decrease in striatal dopamine in an SIV model of HIV-associated neurological disease.

Authors:  Kelly A Meulendyke; Mikhail V Pletnikov; Elizabeth L Engle; Patrick M Tarwater; David R Graham; M Christine Zink
Journal:  J Neuroimmune Pharmacol       Date:  2011-12-27       Impact factor: 4.147

5.  Targeting the overproduction of peroxynitrite for the prevention and reversal of paclitaxel-induced neuropathic pain.

Authors:  Timothy Doyle; Zhoumou Chen; Carolina Muscoli; Leesa Bryant; Emanuela Esposito; Salvatore Cuzzocrea; Concetta Dagostino; Jan Ryerse; Smita Rausaria; Andrew Kamadulski; William L Neumann; Daniela Salvemini
Journal:  J Neurosci       Date:  2012-05-02       Impact factor: 6.167

Review 6.  Minocycline: therapeutic potential in psychiatry.

Authors:  Olivia M Dean; João Data-Franco; Francesco Giorlando; Michael Berk
Journal:  CNS Drugs       Date:  2012-05-01       Impact factor: 5.749

7.  Mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways.

Authors:  Gerwyn Morris; Michael Maes
Journal:  Metab Brain Dis       Date:  2013-09-10       Impact factor: 3.584

8.  An automated Fpg-based FADU method for the detection of oxidative DNA lesions and screening of antioxidants.

Authors:  Nathalie Müller; Maria Moreno-Villanueva; Arthur Fischbach; Joachim Kienhöfer; Rita Martello; Peter C Dedon; Volker Ullrich; Alexander Bürkle; Aswin Mangerich
Journal:  Toxicology       Date:  2013-05-21       Impact factor: 4.221

9.  Targets of vascular protection in acute ischemic stroke differ in type 2 diabetes.

Authors:  Aisha I Kelly-Cobbs; Roshini Prakash; Weiguo Li; Bindu Pillai; Sherif Hafez; Maha Coucha; Maribeth H Johnson; Safia N Ogbi; Susan C Fagan; Adviye Ergul
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-01-18       Impact factor: 4.733

10.  Cardioprotective and hepatoprotective effects of Citrus hystrix peels extract on rats model.

Authors:  Herwandhani Putri; Standie Nagadi; Yonika Arum Larasati; Nindi Wulandari; Adam Hermawan; Agung Endo Nugroho
Journal:  Asian Pac J Trop Biomed       Date:  2013-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.